US regulators said today they will allow Biogen and Elan to resume use of their multiple sclerosis drug Tysabri in patients who had previously been taking it as part of a study.
The Food and Drug Administration said it will decide in late March whether the companies can resume widespread sales of the drug, which were halted after reports of a serious brain ailment in a small number of patients.
